Selective Treg modulator gotistobart (BNT316/ONC-392) showed a reduction in the risk of death by more than half compared to standard of care chemotherapy and a manageable safety profile in the first ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback